Enalapril/Hydrochlorothiazide Teva may be available in the countries listed below.
Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Enalapril/Hydrochlorothiazide Teva in the following countries:
Hydrochlorothiazide is reported as an ingredient of Enalapril/Hydrochlorothiazide Teva in the following countries:
International Drug Name Search
Aspirin Complex may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Aspirin Complex in the following countries:
Pseudoephedrine is reported as an ingredient of Aspirin Complex in the following countries:
Pseudoephedrine hydrochloride (a derivative of Pseudoephedrine) is reported as an ingredient of Aspirin Complex in the following countries:
International Drug Name Search
Andapsin may be available in the countries listed below.
Sucralfate is reported as an ingredient of Andapsin in the following countries:
International Drug Name Search
se-LE-ji-leen
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies with major depressive disorder (MDD) and other psychiatric disorders. Short term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24, and there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. This risk must be balanced with the clinical need. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. The transdermal patch should not be used in pediatric patients under the age of 12, at any dose, even with dietary modifications .
In the U.S.
Available Dosage Forms:
Therapeutic Class: Antidepressant
Pharmacologic Class: Monoamine Oxidase Inhibitor, Type B
Selegiline transdermal is used to treat mental depression. selegiline is a monoamine oxidase (MAO) inhibitor .
selegiline is available only with your doctor's prescription .
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For selegiline, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to selegiline or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Appropriate studies performed to date have not demonstrated any benefit to using selegiline transdermal in children with depression. Studies have shown that some children, teenagers, and young adults think about suicide or attempt suicide when taking selegiline. Because of this toxicity, use in children is not recommended .
Selegiline transdermal should not be used in children below 12 years of age .
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of selegiline transdermal in the elderly .
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | C | Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. |
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking selegiline, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using selegiline with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.
Using selegiline with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Using selegiline with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using selegiline with any of the following is usually not recommended, but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use selegiline, or give you special instructions about the use of food, alcohol, or tobacco.
The presence of other medical problems may affect the use of selegiline. Make sure you tell your doctor if you have any other medical problems, especially:
selegiline comes with a Medication Guide. Read and follow these instructions carefully. Ask your doctor or pharmacist if you have any questions .
To use the skin patch:
Do not stop using selegiline without asking your doctor. If you have not used your medicine for several days in a row, do not start using it again without talking to your doctor first .
The dose of selegiline will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of selegiline. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you forget to wear or change a patch, put one on as soon as you can. If it is almost time to put on your next patch, wait until then to apply a new patch and skip the one you missed. Do not apply extra patches to make up for a missed dose.
Store the patches at room temperature in a closed container, away from heat, moisture, and direct light.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
It is very important that your doctor check your progress at regular visits to make sure selegiline is working properly and to check for unwanted effects .
Selegiline transdermal may cause some people to be agitated, irritable, or display other abnormal behaviors. It may also cause some people to have suicidal thoughts and tendencies or to become more depressed. If you, your child, or your caregiver notice any of these side effects, tell your doctor or your child's doctor right away .
When selegiline transdermal is used at low doses, there are no restrictions on food or beverages you eat or drink. However, the chance exists that dangerous reactions, such as sudden high blood pressure, may occur if higher doses are used with certain foods or beverages. These foods or beverages include foods that have a high tyramine content (most common in foods that are aged or fermented to increase their flavor), such as cheeses; fava or broad bean pods; yeast or meat extracts; smoked or pickled meat, poultry, or fish; fermented sausage (bologna, pepperoni, salami, summer sausage) or other fermented meat; sauerkraut; any spoiled or improperly stored meat, poultry, fish, or animal livers; or any overripe fruit. These may also include alcoholic beverages or alcohol-free or reduced-alcohol beer and wine. Also, for at least 2 weeks after you stop using selegiline, these foods or beverages may continue to react with selegiline transdermal. If a list of these foods and beverages is not given to you, ask your health care professional to provide one .
Check with your doctor or hospital emergency room immediately if severe headache, stiff neck, chest pains, fast heartbeat, or nausea and vomiting occur while you are using selegiline. These may be symptoms of a serious side effect that should have a doctor's attention .
You should not use selegiline if you are taking other medicines to treat depression (such as amitriptyline, bupropion, doxepin, duloxetine, fluoxetine, imipramine, mirtazapine, nortriptyline, paroxetine, sertraline, venlafaxine, Celexa®, Cymbalta®, Effexor®, Elavil®, Lexapro™, Paxil®, Prozac®, Tofranil®, Wellbutrin®, or Zoloft®), anxiety medicine (such as buspirone or BuSpar®), MAO inhibitors (MAOI) (such as Eldepryl®, Marplan®, Nardil®, or Parnate®), St. John's wort, or pain medicines (such as meperidine, methadone, propoxyphene, tramadol, Darvon®, Demerol®, Dolophine®, or Ultram®). Do not use selegiline if you are taking seizure medicines (such as carbamazepine, oxcarbazepine, Tegretol®, or Trileptal®), cough medicines (such as dextromethorphan or Benylin®), medicine to treat muscle spasms (such as cyclobenzaprine or Flexeril®), over-the-counter diet pills, herbal weight-loss products, cold medicines (such as ephedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, Neo-Synephrine®, Novafed®, or Sudafed®), any herbal or dietary supplement that contains tyramine, or medicines called amphetamines (also called stimulants or "uppers"). Do not use selegiline if you take selegiline capsules or tablets .
Before you have any kind of surgery, tell the medical doctor in charge that you are taking selegiline. Using selegiline together with medicines that are sometimes used during surgery may increase the effects of these medicines .
Dizziness, lightheadedness, or fainting may occur, especially when you get up from a lying or sitting position. Getting up slowly may help. If the problem continues or gets worse, check with your doctor .
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: selegiline Transdermal side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Athymil may be available in the countries listed below.
Mianserin hydrochloride (a derivative of Mianserin) is reported as an ingredient of Athymil in the following countries:
International Drug Name Search
Generic Name: tetanus immune globulin (Intramuscular route)
TET-a-nus i-MUNE GLOB-ue-lin
In the U.S.
Available Dosage Forms:
Therapeutic Class: Immune Serum
Tetanus immune globulin is used to prevent tetanus infection (also known as lockjaw). Tetanus is a serious illness that causes convulsions (seizures) and severe muscle spasms that can be strong enough to cause bone fractures of the spine. Tetanus causes death in 30 to 40 percent of cases.
In recent years, two thirds of all tetanus cases have been in persons 50 years of age and older. A tetanus infection in the past does not make you immune to tetanus in the future.
Tetanus immune globulin works by giving your body the antibodies it needs to protect it against tetanus infection. This is called passive protection. This passive protection lasts long enough to protect your body until your body can produce its own antibodies against tetanus.
Tetanus immune globulin is to be administered only by or under the supervision of your doctor or other health care professional.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Although there is no specific information comparing use of tetanus immune globulin in children with use in other age groups, this medicine is not expected to cause different side effects or problems in children than it does in adults.
Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of tetanus immune globulin in the elderly with use in other age groups. However, there is no evidence that the effects of tetanus immune globulin in older adults differ from those in younger persons.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | C | Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. |
Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of tetanus immune globulin. Make sure you tell your doctor if you have any other medical problems.
This section provides information on the proper use of a number of products that contain tetanus immune globulin. It may not be specific to HyperTET S/D. Please read with care.
The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: HyperTET S/D side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Fluconazol Richet may be available in the countries listed below.
Fluconazole is reported as an ingredient of Fluconazol Richet in the following countries:
International Drug Name Search
Aspirina C may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Aspirina C in the following countries:
Ascorbic Acid is reported as an ingredient of Aspirina C in the following countries:
International Drug Name Search
Croma may be available in the countries listed below.
Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Croma in the following countries:
Tetryzoline hydrochloride (a derivative of Tetryzoline) is reported as an ingredient of Croma in the following countries:
International Drug Name Search
Amlodipina Bluepharma may be available in the countries listed below.
Amlodipine is reported as an ingredient of Amlodipina Bluepharma in the following countries:
International Drug Name Search
Cholestad may be available in the countries listed below.
Simvastatin is reported as an ingredient of Cholestad in the following countries:
International Drug Name Search
Minalerg may be available in the countries listed below.
Budesonide is reported as an ingredient of Minalerg in the following countries:
International Drug Name Search
Generic Name: hexaminolevulinate (Urinary bladder route)
hex-a-mee-noe-LEV-ue-lin-ate hye-droe-KLOR-ide
In the U.S.
Available Dosage Forms:
Therapeutic Class: Diagnostic Agent, Radiopharmaceutical Imaging
Hexaminolevulinate is an imaging agent that is used in a procedure for the bladder called cystoscopy. Imaging agents help create an image or picture of body parts, such as the bladder. Hexaminolevulinate is used to check for cancer cells in the bladder.
This medicine is to be used only by or under the direct supervision of a doctor.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Appropriate studies have not been performed on the relationship of age to the effects of hexaminolevulinate in the pediatric population. Safety and efficacy have not been established.
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of hexaminolevulinate in the elderly.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:
A nurse or other trained health professional will give you this medicine in a hospital or clinic. This medicine is given through a tube (catheter) that is placed in your bladder.
The tube will be taken out and the medicine must be held in the bladder for at least 1 hour. You may stand, sit, or move during this time. If you feel you cannot hold the medicine in the bladder for 1 hour, tell your doctor or nurse right away.
This medicine may cause a serious type of allergic reaction called anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Tell your doctor or nurse right away if you have a rash; itching; hoarseness; swelling of your hands, face, or mouth; trouble with breathing or swallowing; or chest pain after you receive the medicine.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: Cysview side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Phoslax may be available in the countries listed below.
Sodium Phosphate is reported as an ingredient of Phoslax in the following countries:
International Drug Name Search
Rantin may be available in the countries listed below.
Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Rantin in the following countries:
International Drug Name Search
Avicas may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Febantel is reported as an ingredient of Avicas in the following countries:
International Drug Name Search
AeroBec Autohaler may be available in the countries listed below.
Beclometasone is reported as an ingredient of AeroBec Autohaler in the following countries:
Beclometasone 17α,21-dipropionate (a derivative of Beclometasone) is reported as an ingredient of AeroBec Autohaler in the following countries:
International Drug Name Search
Amitriptilin R. Desitin may be available in the countries listed below.
Amitriptyline hydrochloride (a derivative of Amitriptyline) is reported as an ingredient of Amitriptilin R. Desitin in the following countries:
International Drug Name Search
Ketoisdin Vaginal may be available in the countries listed below.
Ketoconazole is reported as an ingredient of Ketoisdin Vaginal in the following countries:
International Drug Name Search
Aspirin forte may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Aspirin forte in the following countries:
Caffeine is reported as an ingredient of Aspirin forte in the following countries:
International Drug Name Search
Paroxetina Davur may be available in the countries listed below.
Paroxetine hydrochloride (a derivative of Paroxetine) is reported as an ingredient of Paroxetina Davur in the following countries:
International Drug Name Search
Acido Acetilsalicilico + Acido Ascorbico Coop may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Acido Acetilsalicilico + Acido Ascorbico Coop in the following countries:
Ascorbic Acid is reported as an ingredient of Acido Acetilsalicilico + Acido Ascorbico Coop in the following countries:
International Drug Name Search
Synacthen Depot may be available in the countries listed below.
Tetracosactide is reported as an ingredient of Synacthen Depot in the following countries:
Tetracosactide acetate (a derivative of Tetracosactide) is reported as an ingredient of Synacthen Depot in the following countries:
Tetracosactide zinc (a derivative of Tetracosactide) is reported as an ingredient of Synacthen Depot in the following countries:
International Drug Name Search
Alcamex may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Alcamex in the following countries:
International Drug Name Search
Amlodibene may be available in the countries listed below.
Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Amlodibene in the following countries:
International Drug Name Search
Avimox may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Avimox in the following countries:
International Drug Name Search
Asthalin may be available in the countries listed below.
Salbutamol is reported as an ingredient of Asthalin in the following countries:
Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Asthalin in the following countries:
International Drug Name Search
Colistine LACTO may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Colistin sulfate (a derivative of Colistin) is reported as an ingredient of Colistine LACTO in the following countries:
International Drug Name Search
Acide oxoglurique may be available in the countries listed below.
Acide oxoglurique (DCF) is also known as Ketoglutaric acid
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
In some countries, this medicine may only be approved for veterinary use.
In the US, Benazepril (benazepril systemic) is a member of the drug class angiotensin converting enzyme inhibitors and is used to treat Diabetic Kidney Disease, Heart Failure, High Blood Pressure and Left Ventricular Dysfunction.
US matches:
Rec.INN
C09AA07
0086541-75-5
C24-H28-N2-O5
424
ACE inhibitor
1H-1-Benzazepine-1-acetic acid, 3-[[1-(ethoxycarbonyl)-3-phenylpropyl]-amino]-2,3,4,5-tetrahydro-2-oxo-, [S-(R*,R*)]-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| BANM | British Approved Name (Modified) |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Amlodipina Medineo may be available in the countries listed below.
Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Amlodipina Medineo in the following countries:
International Drug Name Search
Preventing chronic chest pain caused by heart disease. It also may be used for other conditions as determined by your doctor.
Nitro-Dur Patch is a nitrate. It works by relaxing (widening) blood vessels. Chest pain occurs when the heart needs more oxygen than it can get. Relaxing blood vessels allows blood to flow more easily. This reduces the heart's workload and the amount of oxygen needed by the heart.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Nitro-Dur Patch. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Nitro-Dur Patch. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Nitro-Dur Patch may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Nitro-Dur Patch as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Nitro-Dur Patch.
When used for long periods of time without a break, Nitro-Dur Patch may not work as well. This is known as TOLERANCE. Increasing the dose is not effective in managing tolerance to Nitro-Dur Patch. Tolerance to other nitrates or nitrites may also occur. Be sure to have a "nitrate-free" period of time each day to help prevent this tolerance. Talk with your doctor if Nitro-Dur Patch stops working well. Do not take more than prescribed.
Some people who use Nitro-Dur Patch for a long time without a break may develop a physical need to continue taking it. This is known as physical DEPENDENCE. If you use Nitro-Dur Patch without a break and then suddenly stop using it, you may get WITHDRAWAL symptoms. These may include chest pain, heart attack, or possibly sudden death. Be sure to have a "nitrate-free" period of time each day; this may help prevent dependence and withdrawal problems.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Dizziness, lightheadedness, or fainting when sitting up or standing; flushing of face and neck; headache; irritation at site of patch; nausea; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blurred vision; dry mouth; fainting; flushing; heavy sweating; irregular heartbeat; new or worsening chest pain; pale skin; pounding in the chest; rapid heartbeat; severe dizziness or headache; severe or persistent nausea or vomiting; shortness of breath; slow heartbeat; swelling of the hands, ankles, or feet; unusual weakness.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Nitro-Dur side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include cold or blue skin; confusion; diarrhea; excessive sweating; fainting; fast, slow, or irregular heartbeat; persistent throbbing headache; seizures; trouble breathing; vision problems.
Store Nitro-Dur Patch at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Nitro-Dur Patch out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Nitro-Dur Patch. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Anavenol may be available in the countries listed below.
Dihydroergocristine mesilate (a derivative of Dihydroergocristine) is reported as an ingredient of Anavenol in the following countries:
International Drug Name Search
Fulpan may be available in the countries listed below.
Domperidone is reported as an ingredient of Fulpan in the following countries:
Pantoprazole is reported as an ingredient of Fulpan in the following countries:
International Drug Name Search
Generic Name: Prussian Blue
Class: Other Ion-removing Agents
VA Class: AD900
Chemical Name: Ferric hexacyanoferrate (II)
Molecular Formula: Fe4[Fe(CN)6]3
CAS Number: 14038-43-8
A crystal lattice of ferric hexacyanoferrate (II); an ion-exchange medium with high affinity for cesium and thallium, including radioactive isotopes of these metals.1 3
Treatment of known or suspected internal contamination with radioactive cesium and/or radioactive or nonradioactive thallium following accidental exposure and/or intentional exposure from radioactive terrorism or warfare.1 2 3 4 5 6 Reduces the risk of death and major morbidity following exposure to these metals.2 4
Treatment of radioactive exposures when the nature of the radioactive contamination is unknown.1 2
For severe thallium intoxication, may need to employ additional measures (e.g., induction of emesis followed by gastric intubation and lavage, forced diuresis, charcoal hemoperfusion, hemodialysis) to enhance thallium elimination.1 7
Initiate therapy as soon as possible after contamination is suspected.1
Cesium poisoning: Determine baseline internalized137Cs contamination (by whole-body counting, bioassay, or urine/feces sampling) if possible.1 Measure radioactivity counts in urine and feces weekly to monitor137Cs elimination rate.1 Assess whole-body radioactivity after 30 days of therapy.1
Thallium poisoning: Determine baseline internalized thallium contamination (by whole-body counting and/or bioassay) if possible.1 Monitor CBC and serum chemistry and electrolytes weekly during therapy.1
Administer orally with food to stimulate excretion of cesium or thallium.1
If patients cannot tolerate swallowing large numbers of capsules, open the capsules and mix the contents with bland food or liquids.1
Use with appropriate measures (i.e., oral fiber-based laxatives and/or a high-fiber diet) to promote regular fecal elimination.1
Can be given with 15% mannitol to prevent constipation.3 7 8
Children 2–12 years of age: 1 g 3 times daily.1
Children ≥13 years of age: 3 g 3 times daily.1 Once internal radiation has decreased substantially, reduce dosage to 1 or 2 g 3 times daily (to improve GI tolerance).1
Continue for a minimum of 30 days.1 Duration of therapy based on level of contamination and clinical judgment.1
Children 2–12 years of age: 1 g 3 times daily.1
Children ≥13 years of age: 3 g 3 times daily.1
Duration of therapy based on level of contamination and clinical judgment.1
3 g 3 times daily.1 Once internal radiation has decreased substantially, reduce dosage to 1 or 2 g 3 times daily (to improve GI tolerance).1
Continue for a minimum of 30 days.1 Duration of therapy based on level of contamination and clinical judgment.1
3 g 3 times daily.1
Duration of therapy based on level of contamination and clinical judgment.1
No special population dosage recommendations at this time.1
No contraindications according to manufacturer.1
Effective only in decreasing radiation exposure; does not treat complications of such exposure.1 Provide supportive treatment for radiation toxicity (e.g., for severe neutropenia and thrombocytopenia) in conjunction with prussian blue therapy.1
In radiologic emergencies, the type of elemental exposure may not be known.1 Prussian blue may not bind to all radioactive elements; therefore, may need to use other radioprotectants (e.g., potassium iodide, edetate calcium disodium, sodium alginate) in addition to prussian blue in patients contaminated with unknown or multiple radioactive elements.1 2
Constipation reported frequently; constipation responds to oral administration of fiber (i.e., fiber-based laxatives and/or a high-fiber diet).1 3 4
Decreased GI motility will slow the GI transit time of the prussian blue-metal complex (i.e., prussian blue-137Cs, prussian blue-thallium) and may increase exposure to the metal.1 Caution in individuals with conditions associated with decreased GI motility.1
Hypokalemia (serum potassium concentrations of 2.5–2.9 mEq/L) reported.1 3 Closely monitor serum electrolytes.1
Use with caution in individuals with preexisting cardiac arrhythmias or electrolyte imbalances.1
Category C.1
Prussian blue is unlikely to distribute into breast milk.1
Cesium and thallium are distributed into human breast milk; women contaminated with these metals should not breast-feed.1
Safety and efficacy and dosage recommendations in pediatric patients ≥2 years of age extrapolated from adult data and supported by experience in pediatric patients (4–12 years of age).1
Dosing recommendations not established for pediatric patients <2 years of age.1
Use not contraindicated; however, may be less effective in these patients due to decreased excretion of cesium and/or thallium in the bile.1
Use not contraindicated.1
Constipation,1 3 4 GI distress,1 4 blue discoloration of sweat and tears (long-term administration).7
Possible pharmacokinetic interaction (binding of prussian blue to drug and/or essential nutrient).1 Monitor serum concentrations and/or clinical response in patients receiving clinically important drugs.1
Drug | Interaction | Comments |
|---|---|---|
Radioprotectants | Pharmacologic interaction unlikely; not expected to affect efficacy of prussian blue in the management of137Cs poisoning1 |
|
Tetracycline, oral | Possible pharmacokinetic interaction (decreased bioavailability of tetracycline)1 | Monitor serum concentrations of and/or clinical response to tetracycline1 |
Not appreciably absorbed through intact GI wall.1 7
Eliminated unchanged in feces.1 Clearance depends on GI transit time.1 7
In the dark at 25°C (may be exposed to 15–30°C).1
An ion-exchange medium with high affinity for cesium and thallium, including radioactive isotopes of these metals.1
Binds cesium and/or thallium in the GI tract, thus preventing absorption or reabsorption of these metals and increasing the rate of their elimination as insoluble complexes in feces.1
Reduces whole-body effective half-life of cesium and mean serum biologic half-life of thallium.1 4
May bind other elements (e.g., potassium).1 (See Hypokalemia under Cautions.)
Importance of taking prussian blue with food; importance of taking appropriate measures (i.e., oral fiber-based laxatives and/or a high-fiber diet) to promote regular fecal elimination.1
Importance of instructing patients on safety measures that should be used to minimize radiation exposure to others, including appropriate disposal of urine and feces.1 Clothing contaminated with blood or urine should be washed separately.1
Advise patients of possible bluish appearance of their stools.1
Advise patients who are unable to swallow capsules that their mouth and teeth might be colored blue if prussian blue capsules are opened and the contents mixed with food or liquid.1
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.1
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Capsules | 500 mg | Radiogardase | Heyl Chemisch-pharmazeutische |
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions September 2005. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Heyl Chemisch-pharmazeutische. Radiogardase (insoluble Prussian blue) capsules prescribing information. From the FDA web site (). (Accessed 7 Oct 2003).
2. US Food and Drug Administration. Questions and answers on Prussian Blue. From the FDA web site (). (Accessed 2003 Oct 7.)
3. Thompson DF, Church CO. Prussian blue for treatment of radiocesium poisoning. Pharmacotherapy. 2001; 21:1364-7. [IDIS 472544] [PubMed 11714209]
4. US Food and Drug Administration. Guidance for industry on Prussian blue for treatment of internal contamination with thallium or radioactive cesium; availability. [Docket No. 03D-0023.] Fed Regist. 2003; 68:5645-8.
5. US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: Prussian blue drug products—submitting a new drug application. Rockville, MD: FDA; 2003 Jan.
6. American Academy of Pediatrics. Radiation disasters and children: policy statement. Pediatrics. 2003; 111:1455-66. [PubMed 12777572]
7. Hoffman RS. Thallium toxicity and the role of Prussian blue in therapy. Toxicol Rev. 2003; 22:29-40. [IDIS 511730] [PubMed 14579545]
8. Reviewers’ comments (personal observations).
